HIV subtype, epidemiological and mutational correlations in patients from Paraná, Brazil

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 5, 2010, Pages 495-501

  da Silva, Monica Maria Gomes ^a   Telles, Flavio Queiroz ^b   da Cunha, Clovis Arns ^a,b,c   Rhame, Frank S ^c,d,e  

^a HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e ABBOTT NORTHWESTERN HOSPITAL   (United States)

Author keywords

Aids; Antiretroviral; Brazil; Genetic diversity; HIV; Subtype B; Subtype non B; Subtypes

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CONTROLLED STUDY; DISEASE CLASSIFICATION; EPIDEMIOLOGICAL DATA; FEMALE; HEALTH STATUS; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIAL DIVERSITY; PREVALENCE; RISK FACTOR; SEX RATIO; VIRUS MUTATION;

EID: 78951489322     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702010000500012     Document Type: Article

References (28)

1. HIV Databasis, accessed at http://www.hiv.lanl.gov/content/index, on Oct, 2009.
2. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006; 20:W13-23.
3. Brazilian Minister of Health. Boletim Epidemiologico ano V no 1. 2008 avaiable at www.aids.gov.br.
4. Barreto CC, Nischyia A, Araujo LV, Ferreira JE, Busch MP, Sabino EC. Trends in Antiretroviral Drug Resistance and Clade Distributions among HIV-1-infected Blood Donors in São Paulo, Brazil. J Acquir Immune Defi c Syndr 2006; 41(3):338-41.
5. Martinez AMB, Barbosa EF, Ferreira PCP et al. Molecular Epidemiology of HIV-1 in Rio Grande, RS, Brazil. Rev Soc Med Trop 2002; 35(5):471-6.
6. Locatelli D, Stoco PH, De Queiroz AT et al. Molecular Epidemiology of HIV-1 in Santa Catarina State confirms increases of Subtype C in Southern Brazil. J Med Virol 2007; 79:1455-63.
7. Marins JR, Jamal LF, Chen SY et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003; 17:1675-82.
8. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the Drug Resistance Mutations in HIV-1: December 2008. Topics in Medicine 2008; 16(5):138-44.
9. Deshpande A, Jauvin V, Magnin N et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to ARV. AIDS Res Hum Retroviruses 2007; 23:335-40.
10. Doualla-Bell F, Avalos A, Brenner B et al. High prevalence of K65R mutation in human immunodefi ciency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-5.
11. Couto-Fernandez JC, Morgado MG, Bongertz V et al. HIV-1 subtyping in Salvador, Bahia, Brazil: a city with African sociodemographic characteristics. J Acquir Immune Defi c Syndr 1999; 22(3):288-93.
12. Soares EAJM, Santos RP, Pellegrini JA, Sprinz E, Tanuri A, Soares MA. Epidemiologic and Molecular Characterization of Human Immunodefi ciency Virus Type 1 in Souther Brazil. J Acquir Immune Defi c Syndr 2003; 34(5):520-6.
13. Soares EA, Martinez AM, Souza TM, Santos AF, Hora VD. HIV-1 Subtype C dissemination in Southern Brazil. AIDS 2005; 19(S4):S81-S86.
14. Soares AS, De Oliveira T, Brindeiro RM et al. A specifi c subtype C of human immunodefi ciency virus type 1 circulates in Brazil. AIDS 2003; 17:11-21.
15. Fox J, Dudaz A, Green H. Epidemiology of non-B clade forms of HIV-1 in MSM in the UK [poster 117]. In: Program and abstracts of the 13th Annual Conference of the British HIV Association (Edinburgh, Scotland). British HIV Association, 2007.
16. Geretti AM, Harrison L, Green H et al. UK Collaborative Group on HIV Drug Resistance. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis 2009; 48(9):1296-305.
17. Walter BL, Armitage AE, Graham SC et al. Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility. AIDS 2009; 23:1047-57.
18. Shafer RW, Schapiro JM. HIV-1 Drug Resistance Mutations: un Update Framework for the Second Decade of HAART. AIDS Rev 2008; 10:67-84.
19. Brazilian Minister of Health 2008. Recomendações para Tratamento de Adultos Infectados pelo HIV. Avaiable at www.aids.gov.br.
20. Novitsky V, Wester CW, DeGruttola V et al. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1 C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res Hum Retroviruses 2003; 23:868-78.
21. Grossman Z, Istomin V, Averbuch D et al. Genetic Variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004; 18(6):909-15.
22. Soares EAJM, Santos AFA, Sousa TM et al. Differencial Drug Resistance Acquisition in HIV-1 of Subtypes B and C. PLoS One 2007; 8(e730):1-8.
23. Coutsinos D, Invernizzi CF, Xu H et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodefi ciency virus type 1. J Virol 2009; 83(4):2029-33.
24. Sunpath H, France H, Tarin M et al. Prospective analysis of HIV-1 Drug Resistance After Virologic Failure on Antiretroviral Therapy (ART): Initial Results from a Paediatric Cohort Study from KZN, South Africa. In 15th Conference on Retrovirus and Opportunistic Infections: 2008; Boston, MA.
25. Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS. High prevalence of human immunodefi ciency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007; 23:1303-8.
26. Brenner B, Turner D, Oliveira M et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers crossresistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17(1):F1-5.
27. Kantor R, Katzenstein DA, Efron B et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2(4):e112.
28. Perno C, Cozzi-Lepri F, Forbici A. Minor mutations in HIV protease at baseline and appearance of primary mutation 90M in patients whom their fi rst PI antiretroviral regimen failed. J Infect Dis 2004; 189:1983-7.